Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 592 participants.

Also called NCT05669599

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 592 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05669599
  • EU CT 2023-510470-13-00
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Australia, Canada, Czechia, Germany, Hong Kong SAR China, Hungary, Japan, Poland, South Korea, Spain, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05669599. Randomized; quadruple masking; primary purpose treatment. Start 2023-01-18 (actual); primary completion 2024-10-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus
Condition
Obesity
Condition
Overweight
Condition
Type 2 Diabetes Mellitus
Intervention (Biological)
Maridebart Cafraglutide
Intervention (Drug)
Placebo
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct05669599
Content hash
a7f19f95aa5c61359e61b37d36b7f09679209da2a9fb595c55e1e925e636f5c0